Search Within

Department of Medicine

Formats
  1. Journal Article (19620)
  2. Meeting Abstract (16084)
  3. Review (1158)
  4. Book Section (934)
  5. Editorial (611)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22367)
  2. Hematologic Malignancies, Division of (13308)
  3. Center for Hematologic Malignancies (11082)
  4. GSK Faculty (10658)
  5. Survivorship Research (9352)
  6. Division of Subspecialty Medicine (7560)

More Groups

People
  1. Robert Motzer (1251)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1158)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4216)
  3. American Society of Hematology (4003)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2304)
  6. Nature Publishing Group (2122)

More Publishers

Results (39711)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grünwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Merchan, J. R.; Goh, J. C.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Study EV-103 dose escalation/cohort A: Long-term outcome of enfortumab vedotin + pembrolizumab in first-line (1L) cisplatin-ineligible locally advanced or metastatic urothelial carcinoma (la/mUC) with nearly 4 years of follow-up
    Meeting Abstract

    Gupta, S.; Rosenberg, J. E.; McKay, R. R.; Flaig, T. W.; Petrylak, D. P.; Hoimes, C. J.; Friedlander, T. W.; Bilen, M. A.; Srinivas, S.; Burgess, E. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Clinical utility of next generation sequencing (NGS) on circulating tumor DNA (ctDNA) in patients (pts) with pancreatic cancer (PC)
    Meeting Abstract

    Keane, F.; Saadat, L.; O'Connor, C.; Chou, J. F.; Brannon, A. R.; Cowzer, D.; Crowley, F.; Debnath, N.; Bowman, A.; Xu, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • A phase I/II study of durvalumab and stereotactic ablative body radiotherapy (SABR) in locally advanced (LA) and borderline resectable (BR) pancreatic cancer
    Meeting Abstract

    Tuli, R.; Keane, F.; Schoenfeld, J. D.; O'Connor, C.; White, C.; Chou, J. F.; Schwartz, C.; Larsen, M.; Brenner, R.; Park, W.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Temporal patterns of immune-mediated adverse events (imAEs) with tremelimumab (T) plus durvalumab (D) in the phase 3 HIMALAYA study in unresectable hepatocellular carcinoma (uHCC)
    Meeting Abstract

    Lau, G.; Sangro, B.; Crysler, O. V.; Sukeepaisarnjaroen, W.; Lipatov, O.; Morimoto, Ma.; Archambeaud, I.; Burgio, V.; Tuyet Phuong, L. T.; Chao, Y.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Phase 2 trial of pembrolizumab and olaparib (POLAR) maintenance for patients (pts) with metastatic pancreatic cancer (mPDAC): Two cohorts B non-core homologous recombination deficiency (HRD) and C exceptional response to platinum-therapy
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J. F.; Schwartz, C.; Varghese, A. M.; Larsen, M.; Balogun, F.; Brenner, R.; Yu, K. H.; Diguglielmo, E.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Liposomal irinotecan + 5-fluorouracil/leucovorin + oxaliplatin (NALIRIFOX) versus nab-paclitaxel + gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): 12- and 18-month survival rates from the phase 3 NAPOLI 3 trial
    Meeting Abstract

    O'Reilly, E. M.; Melisi, D.; Macarulla, T.; Pazo Cid, R. A.; Chandana, S. R.; De La Fouchardiere, C.; Dean, A. P.; Kiss, I.; Lee, W. J.; Goetze, T. O.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Results from the pivotal phase (Ph) 2b HERIZON-BTC-01 study: Zanidatamab in previously-treated HER2-amplified biliary tract cancer (BTC)
    Meeting Abstract

    Pant, S.; Fan, J.; Oh, D. Y.; Choi, H. J.; Kim, J. W.; Chang, H. M.; Bao, L.; Sun, H. C.; Macarulla Mercade, T.; Xie, F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Cell free DNA (cfDNA) assessment of esophagogastric (EG) cancer using MSK-ACCESS
    Meeting Abstract

    Cytryn, S. L.; Solit, D. B.; Walch, H. S.; Chatila, W. K.; Maron, S. B.; Vakiani, E.; Brannon, A. R.; Ladanyi, M.; Schultz, N.; Berger, M. F.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save
  • Updated dose escalation results for ReFocus, a first-in-human study of highly selective FGFR2 inhibitor RLY-4008 in cholangiocarcinoma and other solid tumors
    Meeting Abstract

    Borad, M. J.; Schram, A. M.; Kim, R. D.; Kamath, S. D.; Sahai, V.; Dotan, E.; Kelley, R. K.; Ponz-Sarvise, M.; Oh, D. Y.; Yachnin, J.; more...
    Journal of Clinical Oncology (2023)

    Fulltext@MSK | Save